Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Deferred Revenue (2016 - 2025)

Traws Pharma's Current Deferred Revenue history spans 14 years, with the latest figure at $226000.0 for Q1 2025.

  • Quarterly results put Current Deferred Revenue at $226000.0 for Q1 2025, changed 0.0% from a year ago — trailing twelve months through Mar 2025 was $226000.0 (changed 0.0% YoY), and the annual figure for FY2024 was $226000.0, changed 0.0%.
  • Current Deferred Revenue for Q1 2025 was $226000.0 at Traws Pharma, roughly flat from $226000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $227000.0 in Q2 2024 to a low of $226000.0 in Q1 2021.
  • The 5-year median for Current Deferred Revenue is $226000.0 (2021), against an average of $226058.8.
  • The sharpest move saw Current Deferred Revenue changed 0.0% in 2021, then increased 0.44% in 2024.
  • Year by year, Current Deferred Revenue stood at $226000.0 in 2021, then changed by 0.0% to $226000.0 in 2022, then changed by 0.0% to $226000.0 in 2023, then changed by 0.0% to $226000.0 in 2024, then changed by 0.0% to $226000.0 in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $226000.0, $226000.0, and $226000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.